Hepatorenal syndrome

Bibliography

• Epstein M, Berk DP, Hollenbe NK, Renal failure in patients with cirrhosis – role of active vasoconstriction. Am J Med 1970;12:175-85
   Google Scholar
• Epstein M, Schneider N, Befeler B. Relationship of systemic and intrarenal hemodynamics in cirrhosis. J Lab Clin Med 1977;89:1175-87
   PubMed Web of Science ®Google Scholar
• Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;271:1121-5
   PubMed Web of Science ®Google Scholar
• Koppel MH, Coburn JW, Mims MM, Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-71
   PubMed Web of Science ®Google Scholar
• Guevara M, Gines P, Fernandez-Esparrach G, Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41
   PubMed Web of Science ®Google Scholar
• Hadengue A, Gadano A, Moreau R, Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565-70
   PubMed Web of Science ®Google Scholar
• Le Moine O, el Nawar A, Jagodzinski R, Treatment with terlipressin as a bridge to liver transplantation in a patient with hepatorenal syndrome. Acta Gastroenterol Belg 1998;61:268-70
   PubMed Web of Science ®Google Scholar
• Angeli P, Volpin R, Gerunda G, Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7
   PubMed Web of Science ®Google Scholar
• Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999;30:870-5
   PubMed Web of Science ®Google Scholar
• Uriz J, Gines P, Cardenas A, Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:43-8
   PubMed Web of Science ®Google Scholar
• Alessandria C, Venon W, Marzano A. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-8
   PubMed Web of Science ®Google Scholar
• Duvoux C, Zanditenas D, Hezode C, Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. Hepatology 2002;36:374-80
   PubMed Web of Science ®Google Scholar
• Halimi C, Bonnard P, Bernard B, Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153-8
   PubMed Web of Science ®Google Scholar
• Moreau R, Durand F, Poynard T, Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923-30
   PubMed Web of Science ®Google Scholar
• Ortega R, Gines P, Uriz J, Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-8
   PubMed Web of Science ®Google Scholar
• Alessandria C, Ottobrelli A, Debernardi-Venon W, Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007, doi: 10.1016/j.jhep.2007.04.010
   Google Scholar
• Martin-Llahi M, Pepin MN, Guevara M, Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-9
   PubMed Web of Science ®Google Scholar
• Neri S, Pulvirenti D, Malaguarnera M, Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008;53:830-5
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Boyer T, Garcia-Tsao G, A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008;134:1360-8
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Ring-Larsen H, Christensen NJ. Catecholamines in plasma from artery, cubital vein, and femoral vein in patients with cirrhosis. Significance of sampling site. Scand J Clin Lab Invest 1986;46:39-44
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Bendtsen F, Gerbes AL, Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor. Hepatology 1992;16:1163-70
   PubMed Web of Science ®Google Scholar
• Ruiz-del-Arbol L, Urman J, Fernandez J, Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003;38:1210-18
   PubMed Web of Science ®Google Scholar
• Ruiz-del-Arbol L, Monescillo A, Arocena C, Circulatory function and hepatorenal syndrome in cirrhosis 1. Hepatology 2005;42:439-47
   PubMed Web of Science ®Google Scholar
• Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010;59:105-10
   PubMed Web of Science ®Google Scholar
• Salerno F, Gerbes A, Gines P, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis 2. Gut 2007;56:1310-18
   PubMed Web of Science ®Google Scholar
• Arroyo V, Gines P, Gerbes AL, Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol 1996;23:164-76
   Google Scholar
• Follo A, Llovet JM, Navasa M, Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994;20:1495-501
   PubMed Web of Science ®Google Scholar
• Toledo C, Salmeron JM, Rimola A, Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-7
   PubMed Web of Science ®Google Scholar
• Terra C, Guevara M, Torre A, Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005;129:1944-53
   PubMed Web of Science ®Google Scholar
• Fasolato S, Angeli P, Dallagnese L, Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007;45:223-9
   PubMed Web of Science ®Google Scholar
• Frances R, Gonzalez-Navajas JM, Zapater P, Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin Exp Immunol 2007;150:230-7
   PubMed Web of Science ®Google Scholar
• Frances R, Gonzalez-Navajas JM, Zapater P, Bacterial DNA induces the complement system activation in serum and ascitic fluid from patients with advanced cirrhosis. J Clin Immunol 2007;27:438-44
   PubMed Web of Science ®Google Scholar
• Such J, Munoz C, Zapater P, Perez-Mateo M. Bacterial DNA induces a proinflammatory immune response in patients with decompensated cirrhosis. Gut 2005;54(10):1500-1
   PubMed Web of Science ®Google Scholar
• Such J, Frances R, Munoz C, Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002;36:135-41
   PubMed Web of Science ®Google Scholar
• Duseja A, Chawla YK, Dhiman RK, Non-hepatic insults are common acute precipitants in patients with acute on chronic liver failure (ACLF). Dig Dis Sci 2010;55:3188-92
   PubMed Web of Science ®Google Scholar
• Novelli G, Rossi M, Ferretti G, Predictive parameters after molecular absorbent recirculating system treatment integrated with model for end stage liver disease model in patients with acute-on-chronic liver failure. Transplant Proc 2010;42:1182-7
   PubMed Web of Science ®Google Scholar
• Wasmuth HE, Kunz D, Yagmur E, Patients with acute on chronic liver failure display ‘sepsis-like’ immune paralysis. J Hepatol 2005;42:195-201
   PubMed Web of Science ®Google Scholar
• Xing T, Li L, Cao H, Huang J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol 2007;147:184-8
   PubMed Web of Science ®Google Scholar
• Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979;77:215-22
   PubMed Web of Science ®Google Scholar
• Zipser RD, Hoefs JC, Speckart PF, Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979;48:895-900
   PubMed Web of Science ®Google Scholar
• Epstein M, Lifschitz M, Ramachandran M, Rappaport K. Characterization of renal prostaglandin E responsiveness in decompensated cirrhosis: implications for renal sodium handling. Clin Sci (Lond) 1982;63:555-63
   PubMed Web of Science ®Google Scholar
• Zipser RD, Radvan GH, Kronborg IJ, Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983;84:697-703
   PubMed Web of Science ®Google Scholar
• Perez-Ayuso RM, Arroyo V, Camps J, Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984;26:72-80
   PubMed Web of Science ®Google Scholar
• Cabrera J, Arroyo V, Ballesta AM, Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 1982;82:97-105
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-77
   PubMed Web of Science ®Google Scholar
• Guevara M, Fernandez-Esparrach G, Alessandria C, Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatology 2004;40:646-51
   PubMed Web of Science ®Google Scholar
• Cardenas A, Gines P, Uriz J, Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34:671-6
   PubMed Web of Science ®Google Scholar
• Gines P, Arroyo V, Quintero E, Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987;93:234-41
   PubMed Web of Science ®Google Scholar
• Gines P, Angeli P, Lenz K, EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417
   PubMed Web of Science ®Google Scholar
• Moore KP, Wong F, Gines P, The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003;38:258-66
   PubMed Web of Science ®Google Scholar
• Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970;282:1391-6
   PubMed Web of Science ®Google Scholar
• Sugano S. Endotoxin levels in cirrhotic rats with sterile and infected ascites. Gastroenterol Jpn 1992;27:348-53
   PubMedGoogle Scholar
• Heller J, Sogni P, Barriere E, Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000;33:376-81
   PubMed Web of Science ®Google Scholar
• Navasa M, Follo A, Filella X, Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998;27:1227-32
   PubMed Web of Science ®Google Scholar
• Sort P, Navasa M, Arroyo V, Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9
   PubMed Web of Science ®Google Scholar
• Poole B, Schrier RW, Jani A. Glomerular disease in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, editors, Ascites and renal dysfunction in liver disease. 2nd edition. Blackwell Publishing, Malden; 2005. p. 360-70
   Google Scholar
• Crawford DH, Endre ZH, Axelsen RA, Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992;19:339-44
   PubMed Web of Science ®Google Scholar
• Axelsen RA, Crawford DH, Endre ZH, Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 1995;27:237-46
   PubMed Web of Science ®Google Scholar
• Malyszko J. Biomarkers of acute kidney injury in different clinical settings: a time to change the paradigm? Kidney Blood Press Res 2010;33:368-82
   PubMed Web of Science ®Google Scholar
• Ring-Larsen H, Hesse B, Henriksen JH, Christensen NJ. Sympathetic nervous activity and renal and systemic hemodynamics in cirrhosis: plasma norepinephrine concentration, hepatic extraction, and renal release. Hepatology 1982;2:304-10
   PubMed Web of Science ®Google Scholar
• Ring-Larsen H. Renal blood flow in cirrhosis: relation to systemic and portal haemodynamics and liver function. Scand J Clin Lab Invest 1977;37:635-42
   PubMed Web of Science ®Google Scholar
• Reichenbach V, Ros J, Jimenez W. Endogenous cannabinoids in liver disease: many darts for a single target. Gastroenterol Hepatol 2010;33:323-9
   PubMed Web of Science ®Google Scholar
• Schrier RW, Arroyo V, Bernardi M, Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7
   PubMed Web of Science ®Google Scholar
• Genesca J, Gonzalez A, Catalan R, Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. Dig Dis Sci 1999;44:372-6
   PubMed Web of Science ®Google Scholar
• Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 2006;43(2 Suppl 1):S121-31
   Web of Science ®Google Scholar
• Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993;104:1750-4
   PubMed Web of Science ®Google Scholar
• Sikuler E, Groszmann RJ. Hemodynamic studies in long- and short-term portal hypertensive rats: the relation to systemic glucagon levels. Hepatology 1986;6:414-18
   PubMed Web of Science ®Google Scholar
• Fernandez-Varo G, Ros J, Morales-Ruiz M, Nitric oxide synthase 3-dependent vascular remodeling and circulatory dysfunction in cirrhosis. Am J Pathol 2003;162:1985-93
   PubMed Web of Science ®Google Scholar
• Claria J, Jimenez W, Arroyo V, Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991;100:494-501
   PubMed Web of Science ®Google Scholar
• Daskalopoulos G, Pinzani M, Murray N, Effects of captopril on renal function in patients with cirrhosis and ascites. J Hepatol 1987;4:330-6
   PubMed Web of Science ®Google Scholar
• Colmenero J, Bataller R, Sancho-Bru P, Effects of losartan on hepatic expression of non-phagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Physiol Gastrointest Liver Physiol 2009;23:726-34
   Google Scholar
• Maroto A, Gines P, Arroyo V, Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology 1993;17:788-93
   PubMed Web of Science ®Google Scholar
• Sacerdoti D, Merkel C, Bolognesi M, Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. Gastroenterology 1995;108:1152-8
   PubMed Web of Science ®Google Scholar
• Iversen P, Sorensen M, Bak LK, Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology 2009;136:863-71
   PubMed Web of Science ®Google Scholar
• Escorsell Manosa A, Mas Ordeig A. Acute on chronic liver failure. Gastroenterol Hepatol 2010;33:126-34
   PubMed Web of Science ®Google Scholar
• Colle I, Durand F, Pessione F, Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882-8
   PubMed Web of Science ®Google Scholar
• Solanki P, Chawla A, Garg R, Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152-6
   PubMed Web of Science ®Google Scholar
• Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004;40:55-64
   PubMed Web of Science ®Google Scholar
• Esrailian E, Pantangco ER, Kyulo NL, Octreotide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci 2007;52:742-8
   PubMed Web of Science ®Google Scholar
• Skagen C, Einstein M, Lucey MR, Said A. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-5
   PubMed Web of Science ®Google Scholar
• Gluud LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-84
   PubMed Web of Science ®Google Scholar
• Angeli P, Morando F. Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepatic Med Evid Res 2010;2:87-98
   PubMedGoogle Scholar
• Nazar A, Pereira GH, Guevara M, Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2010;51:219-26
   PubMed Web of Science ®Google Scholar
• Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 2008;103:1689-97
   PubMed Web of Science ®Google Scholar
• Guevara M, Gines P, Bandi JC, Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998;28:416-22
   PubMed Web of Science ®Google Scholar
• Brensing KA, Textor J, Perz J, Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000;47:288-95
   PubMed Web of Science ®Google Scholar
• Keller F, Heinze H, Jochimsen F, Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): the role of hemodialysis. Ren Fail 1995;17:135-46
   PubMed Web of Science ®Google Scholar
• Capling R, Bastani B. The clinical course of patients with type 1 hepatorenal syndrome maintained on hemodialysis. Ren Fail 2004;26:563-8
   PubMed Web of Science ®Google Scholar
• Mitzner SR, Stange J, Klammt S, Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplant 2000;6:277-86
   PubMed Web of Science ®Google Scholar
• Wong F, Raina N, Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010;59:381-6
   PubMed Web of Science ®Google Scholar
• Lebrec D, Giuily N, Hadengue A, Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French group of clinicians and a group of biologists. J Hepatol 1996;25:135-44
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Gulberg V, Waggershauser T, Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998;28:683-8
   PubMed Web of Science ®Google Scholar
• Gines P, Uriz J, Calahorra B, Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-47
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Genning C, Reddy KR, The North American study for the treatment of refractory ascites. Gastroenterology 2003;124:634-41
   PubMed Web of Science ®Google Scholar
• Salerno F, Merli M, Riggio O, Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 2004;40:629-35
   PubMed Web of Science ®Google Scholar
• Gonwa TA, Morris CA, Goldstein RM, Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome – experience in 300 patients. Transplantation 1991;51:428-30
   PubMed Web of Science ®Google Scholar
• Gonwa TA, McBride MA, Anderson K, Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006;6:2651-9
   PubMed Web of Science ®Google Scholar
• Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-85
   PubMed Web of Science ®Google Scholar
• Restuccia T, Ortega R, Guevara M, Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004;40:140-6
   PubMed Web of Science ®Google Scholar
• Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Review article: volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 2002;16(Suppl 5):12-23
   PubMedGoogle Scholar
• Fernandez J, Navasa M, Planas R, Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007;133:818-24
   PubMed Web of Science ®Google Scholar
• Akriviadis E, Botla R, Briggs W, Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:1637-48
   PubMed Web of Science ®Google Scholar